Skip to main content
. 2018 Aug 6;14(8):e1007234. doi: 10.1371/journal.ppat.1007234

Fig 7. RIPK1 antagonism during infection rescues HSPCs and HSCs but does not impact bacterial burden or survival.

Fig 7

(A) Schematic of IOE infection and treatment with Necrostatin 1 (Nec1s), which was administered twice/day. (B-D) BM cellularity (B), HSPCs (D) and HSCs (E) in vehicle (Veh)- or Nec1s-treated mock- or infected WT mice 7 d.p.i. n = 4–5 mice/group. *P < 0.05, **P < 0.005, ***P < 0.001, ****P < 0.0001. (E) Survival of IOE-infected WT mice treated with Veh or Nec-1s, as depicted in (A), n = 8 mice/group. (F) Bacterial burden in the spleen of Veh- and Nec-1s-treated IOE-infected WT mice at 7 d.p.i., represented as Dsb copy/50ng total DNA.